$2.91 Billion is the total value of Camber Capital Management LP's 39 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 54.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | Buy | VIATRIS INC | $216,480,000 | +33.1% | 16,000,000 | +33.3% | 7.44% | +48.6% |
| UHS | Buy | UNIVERSAL HLTH SVCS INCcl b | $213,939,000 | +6.6% | 1,650,000 | +13.8% | 7.35% | +19.0% |
| MRK | Buy | MERCK & CO INC | $191,600,000 | +70.1% | 2,500,000 | +66.7% | 6.58% | +89.8% |
| SNY | Buy | SANOFIsponsored adr | $190,380,000 | +31.6% | 3,800,000 | +26.7% | 6.54% | +46.9% |
| GILD | Buy | GILEAD SCIENCES INC | $163,373,000 | +112.6% | 2,250,000 | +104.5% | 5.62% | +137.3% |
| ZBH | Buy | ZIMMER BIOMET HOLDINGS INC | $127,040,000 | +19.7% | 1,000,000 | +37.9% | 4.37% | +33.6% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $98,820,000 | – | 450,000 | +100.0% | 3.40% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $84,347,000 | +6.0% | 575,000 | +27.8% | 2.90% | +18.3% |
| SNY | Buy | SANOFIcall | $75,150,000 | +55.9% | 1,500,000 | +50.0% | 2.58% | +73.9% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $74,291,000 | +60.7% | 825,000 | +65.0% | 2.55% | +79.3% |
| INCY | New | INCYTE CORP | $66,060,000 | – | 900,000 | +100.0% | 2.27% | – |
| BIIB | Buy | BIOGEN INC | $59,980,000 | +182.6% | 250,000 | +233.3% | 2.06% | +215.1% |
| ZYME | Buy | ZYMEWORKS INC | $13,112,000 | -39.8% | 800,000 | +6.7% | 0.45% | -32.8% |
| INGN | New | INOGEN INC | $6,800,000 | – | 200,000 | +100.0% | 0.23% | – |
| NUVA | New | NUVASIVE INC | $5,248,000 | – | 100,000 | +100.0% | 0.18% | – |
| GKOS | New | GLAUKOS CORP | $3,333,000 | – | 75,000 | +100.0% | 0.12% | – |
| SDC | New | SMILEDIRECTCLUB INC | $999,000 | – | 425,000 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.